Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Neoplasms 1Myeloproliferative Disorders 1Glioma 1Cholangiocarcinoma 1

Interventions

Cyclophosphamide 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Whole-Body Irradiation 55Busulfan 54Antilymphocyte Serum 47Cyclosporine 45Methotrexate 38fludarabine 37Filgrastim 37Melphalan 32Radiotherapy 27Cytarabine 27Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Azacitidine 18Sirolimus 15Granulocyte Colony-Stimulating Factor 15Flow Cytometry 14Cyclosporins 14thymoglobulin 13Specimen Handling 13Alemtuzumab 13Biopsy 12venetoclax 10Thiotepa 10Decitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × olutasidenib × Other hematologic neoplasm × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡